We then combine BiFC chaperone screening with genetic and pharmacological manipulation of chaperones to gain a mechanistic understanding of the contributions of protein misfolding and cytosolic chaperones to the ability of a tumor-derived p53 mutant to dominantly interfere with WT function. The gene discussed is TP53; the disease is neoplasm.